GlassScriptPhysician profile
Mark D Chouinard
NPI 1487615316
$12,587.90
in general payments reported to CMS, 2019-2025
36 companies · $2,115 in 2025
The $2,115 reported for 2025 was more than what 84% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,122 · 2020: $787 · 2021: $1,857 · 2022: $2,682 · 2023: $1,688 · 2024: $1,336 · 2025: $2,115.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,120 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,119.55 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,554.70 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $2,526.73 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,276.39 | 2019-2025 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $1,210.47 | 2019-2024 | Xarelto |
| Pfizer INC. | $803.86 | 2019-2025 | |
| Esperion Therapeutics, INC. | $510.06 | 2020-2024 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $500.72 | 2019-2025 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $433.34 | 2019-2025 | Lifevest |
| Merck Sharp & Dohme LLC | $402.37 | 2021-2025 | Verquvo |
| Sanofi-Aventis U.S. LLC | $384.57 | 2019-2021 | |
| Actelion Pharmaceuticals US, INC. | $329.74 | 2019-2022 | |
| Bridgebio Pharma, INC. | $201.71 | 2025 | Attruby |
| Bayer Healthcare Pharmaceuticals INC. | $197.03 | 2022-2025 | |
| Amarin Pharma, INC. | $138.68 | 2019-2021 | |
| Boston Scientific Corporation | $122.67 | 2019-2025 | Watchman Flx, Watchman Access System, Bodyguardian |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $120.14 | 2025 | Amvuttra |
| Kiniksa Pharmaceuticals, LTD. | $99.74 | 2022-2023 | Arcalyst |
| Scpharmaceuticals INC. | $86.81 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $83.85 | 2019-2025 | Evkeeza |
| Abiomed | $83.38 | 2024-2025 | Impella |
| Astrazeneca Pharmaceuticals LP | $77.18 | 2021-2025 | Wainua |
| Lexicon Pharmaceuticals, INC. | $63.55 | 2023-2024 | Inpefa |
| Heartflow, INC. | $51.82 | 2025 | |
| Gilead Sciences, INC. | $50.75 | 2019 | |
| Daiichi Sankyo INC. | $44.18 | 2022-2023 | Injectafer |
| Kiniksa Pharmaceuticals International, Plc | $43.03 | 2024 | Arcalyst |
| Azurity Pharmaceuticals, INC. | $32.32 | 2024 | Edarbi |
| Lundbeck LLC | $23.74 | 2019 | |
| Altathera Pharmaceuticals LLC | $19.82 | 2025 | Sotalol Hydrochloride |
| Zimmer Biomet Holdings, INC. | $19.58 | 2020 | |
| Baxter Healthcare | $19.03 | 2024 | Hillrom - Vest System Model 105 Home Care |
| Genzyme Corporation | $17.62 | 2022 | |
| Impulse Dynamics (USA) INC. | $16.69 | 2022 | |
| Abbott Laboratories | $14.57 | 2021 | |
| Chiesi USA, INC. | $14.37 | 2019 | |
| United Therapeutics Corporation | $12.69 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Chouinard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.